EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Efficacy and Recovery of Remimazolam Versus Midazolam in Sedated Colonoscopy: A Multicenter Randomized Controlled Trial in Japan

Daisuke Yamaguchi iD, Ryoji Ichijima, Hisatomo Ikehara iD, Yosuke Minoda iD, Mitsuru Esaki iD, Ayako Takamori, Akiyoshi Yoh, Moeko Shirouzu, Kento Sadashima, Yutaro Fujimura, Takuya Shimamura, Hironobu Takedomi und 7 weitere

Digestive Endoscopy · 2026

DOI: 10.1111/den.70130 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Digestive Endoscopy, 2026. Verfasst von Daisuke Yamaguchi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan. Hauptthemen laut MEDLINE: Colonoscopy, Midazolam, Hypnotics and Sedatives, Benzodiazepines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mundipharma K.K. (Tokyo, Japan).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Sedation during colonoscopy is becoming increasingly important. Remimazolam, an ultra‐short‐acting benzodiazepine, has a shorter pharmacokinetic half‐life than that of midazolam. This study examined whether remimazolam provides superior sedation during colonoscopy in Japanese patients.

Methods

This prospective, multicenter, randomized, single‐blind, controlled trial included adults (18–80 years) scheduled for sedated colonoscopy. Participants were randomized to the remimazolam and midazolam groups. The primary outcome was the proportion of ambulatory patients 5 min after colonoscopy. Secondary outcomes were successful pre‐procedure sedation (Modified Observer's Assessment of Alertness/Sedation [MOAA/S] ≤ 4), recovery time, total sedative dose, and adverse events.

Results

Forty patients were enrolled and analyzed (remimazolam, n = 19; midazolam, n = 21). At 5 min post‐colonoscopy, ambulation was achieved in 100% (19/19) of remimazolam patients and 19.1% (4/21) of midazolam patients ( p < 0.0001). The median time [interquartile range (IQR)] from procedure end to full alertness (MOAA/S = 5) was 0 [0–0] min for remimazolam and 10 [5–20] min for midazolam ( p < 0.0001). The median time [IQR] from procedure end to independent ambulation was 0 [0–5] min for remimazolam and 20 [10–30] min for midazolam ( p < 0.001). Pre‐procedure sedation was successful (MOAA/S ≤ 4) in 100% of both groups. The median amount [IQR] of total sedative dose was 5 [4–6] mg for remimazolam and 3 [3] mg for midazolam. Hypoxemia occurred in 5.3% and 9.5% of patients in the remimazolam and midazolam groups, respectively.

Conclusions

Compared with midazolam, remimazolam resulted in significantly faster recovery after colonoscopy in Japanese patients, with comparable achievement of target sedation and a low incidence of hypoxemia. Clinical Registration Trial number: jRCTs071240062

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColonoscopyMidazolamHypnotics and SedativesBenzodiazepinesProcedural SedationHumansFemaleMaleMiddle AgedAgedSingle-Blind MethodJapanProspective StudiesAdultAged, 80 and overAnesthesia Recovery PeriodTreatment OutcomeYoung AdultAdolescent

Stichwörter der Autor:innen

Modified Observer's Assessment of Alertness/Sedation scalecolonoscopymidazolamremimazolamsedation

Substanzen

MidazolamHypnotics and SedativesremimazolamBenzodiazepines

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
  • Department of Gastroenterology, Saiseikai Kawaguchi General Hospital, Kawaguchi, Japan.
  • Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
  • Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Clinical Research Center, Saga University Hospital, Saga, Japan.

ORCID-Profile: Daisuke Yamaguchi, Hisatomo Ikehara, Yosuke Minoda, Mitsuru Esaki, Motohiro Esaki

Förderung

  • Mundipharma K.K. (Tokyo, Japan)

Zitieren

APA

Yamaguchi, D., Ichijima, R., Ikehara, H., Minoda, Y., Esaki, M., Takamori, A., Yoh, A., Shirouzu, M., Sadashima, K., Fujimura, Y., Shimamura, T., Takedomi, H., Akutagawa, T., Tsuruoka, N., Sakata, Y., Wada, T., Kusano, C., Shimoda, R., & Esaki, M. (2026). Efficacy and Recovery of Remimazolam Versus Midazolam in Sedated Colonoscopy: A Multicenter Randomized Controlled Trial in Japan. Digestive Endoscopy. https://doi.org/10.1111/den.70130

Vancouver

Yamaguchi D, Ichijima R, Ikehara H, Minoda Y, Esaki M, Takamori A, et al. Efficacy and Recovery of Remimazolam Versus Midazolam in Sedated Colonoscopy: A Multicenter Randomized Controlled Trial in Japan. Digestive Endoscopy. 2026. doi:10.1111/den.70130

BibTeX
@article{Yamaguchi2026,
  author = {Yamaguchi, Daisuke and Ichijima, Ryoji and Ikehara, Hisatomo and Minoda, Yosuke and Esaki, Mitsuru and Takamori, Ayako and Yoh, Akiyoshi and Shirouzu, Moeko and Sadashima, Kento and Fujimura, Yutaro and Shimamura, Takuya and Takedomi, Hironobu and Akutagawa, Takashi and Tsuruoka, Nanae and Sakata, Yasuhisa and Wada, Takuya and Kusano, Chika and Shimoda, Ryo and Esaki, Motohiro},
  title = {Efficacy and Recovery of Remimazolam Versus Midazolam in Sedated Colonoscopy: A Multicenter Randomized Controlled Trial in Japan},
  journal = {Digestive Endoscopy},
  year = {2026},
  doi = {10.1111/den.70130}
}
Kostenlos starten →